Clinical and molecular features of acquired resistance to immunotherapy in non-small cell lung cancerDanish Memon, Matthew D. Hellmann, Kyung Jin Yoo et al.|Cancer Cell|2024Cited by 177
Circulating Tumor DNA Analysis to Assess Risk of Progression after Long-term Response to PD-(L)1 Blockade in NSCLCMatthew D. Hellmann, Maximilian Diehn, Barzin Y. Nabet et al.|Clinical Cancer Research|2020Cited by 123
Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance statusJoao V. Alessi, Mark M. Awad, Biagio Ricciuti et al.|Journal for ImmunoTherapy of Cancer|2020Cited by 58
Torin2 enhances the radiosensitivity of MCF‑7 breast cancer cells by downregulating the mTOR signaling pathway and ATM phosphorylationJia Luo, Ge Wang|Molecular Medicine Reports|2017Cited by 14